{"id":65711,"date":"2026-05-19T23:16:43","date_gmt":"2026-05-19T15:16:43","guid":{"rendered":"https:\/\/flcube.com\/?p=65711"},"modified":"2026-05-19T23:16:44","modified_gmt":"2026-05-19T15:16:44","slug":"leads-biolabs-opamtistomig-becomes-worlds-first-4-1bb-bispecific-antibody-to-enter-pivotal-phase-iii-for-ep-nec","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=65711","title":{"rendered":"Leads Biolabs&#8217; Opamtistomig Becomes World&#8217;s First 4-1BB Bispecific Antibody to Enter Pivotal Phase III for EP-NEC"},"content":{"rendered":"\n<p><strong>Nanjing Leads Biolabs Co., Ltd.<\/strong> (<a href=\"https:\/\/www.google.com\/finance\/quote\/9887:HKG\">HKG: 9887<\/a>) announced it has received <strong>regulatory clearance in China<\/strong> to initiate a <strong>Phase III clinical study<\/strong> evaluating <strong>opamtistomig (LBL-024)<\/strong> in combination with <strong>platinum chemotherapy<\/strong> for patients with <strong>advanced extrapulmonary neuroendocrine carcinoma (EP-NEC)<\/strong>. The bispecific antibody represents the <strong>world&#8217;s first molecule targeting the co-stimulatory receptor 4-1BB<\/strong> to advance to a <strong>single-arm pivotal clinical stage<\/strong>, leveraging Leads Biolabs&#8217; proprietary <strong>X-body technology platform<\/strong>.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-clinical-development-milestone\">Clinical Development Milestone<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Parameter<\/th><th>Details<\/th><\/tr><\/thead><tbody><tr><td><strong>Trial Phase<\/strong><\/td><td>Phase III (pivotal, single-arm)<\/td><\/tr><tr><td><strong>Patient Population<\/strong><\/td><td>Advanced extrapulmonary neuroendocrine carcinoma (EP-NEC)<\/td><\/tr><tr><td><strong>Combination Therapy<\/strong><\/td><td>Opamtistomig + platinum chemotherapy<\/td><\/tr><tr><td><strong>Regulatory Status<\/strong><\/td><td>China regulatory clearance obtained<\/td><\/tr><tr><td><strong>Global Distinction<\/strong><\/td><td>First 4-1BB-targeting molecule in pivotal clinical development<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-drug-profile-amp-innovative-mechanism\">Drug Profile &amp; Innovative Mechanism<\/h2>\n\n\n\n<p><strong>Opamtistomig (LBL-024)<\/strong> represents a <strong>breakthrough bispecific antibody design<\/strong>:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Targets<\/strong>: Dual targeting of <strong>PD-L1 and 4-1BB<\/strong> co-stimulatory receptor<\/li>\n\n\n\n<li><strong>Structure<\/strong>: <strong>2:2 structural design<\/strong> enabling simultaneous engagement of both targets<\/li>\n\n\n\n<li><strong>Mechanism<\/strong>: <strong>Relieves PD-1\/PD-L1-mediated immunosuppression<\/strong> while <strong>enhancing 4-1BB-modulated T-cell activation<\/strong><\/li>\n\n\n\n<li><strong>Synergistic Effect<\/strong>: Dual action achieves <strong>potent anti-tumor activity<\/strong> exceeding monotherapy approaches<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-proprietary-technology-platform\">Proprietary Technology Platform<\/h2>\n\n\n\n<p>The drug is developed using Leads Biolabs&#8217; <strong>patented X-body technology platform<\/strong>:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Platform Innovation<\/strong>: Enables precise engineering of complex bispecific antibody architectures<\/li>\n\n\n\n<li><strong>Structural Control<\/strong>: 2:2 design ensures optimal target engagement and signaling modulation<\/li>\n\n\n\n<li><strong>Safety Optimization<\/strong>: Platform designed to minimize cytokine release syndrome risks associated with 4-1BB agonists<\/li>\n\n\n\n<li><strong>Manufacturing Capability<\/strong>: Demonstrates Leads Biolabs&#8217; ability to produce complex biologics at commercial scale<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-market-opportunity-amp-unmet-need\">Market Opportunity &amp; Unmet Need<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>EP-NEC Burden<\/strong>: Rare but aggressive cancer with <strong>limited treatment options<\/strong> and poor prognosis<\/li>\n\n\n\n<li><strong>Current Standard<\/strong>: Platinum-based chemotherapy provides modest benefit with <strong>median survival of 8-12 months<\/strong><\/li>\n\n\n\n<li><strong>Immunotherapy Gap<\/strong>: PD-1\/PD-L1 inhibitors show limited efficacy in neuroendocrine carcinomas<\/li>\n\n\n\n<li><strong>Commercial Potential<\/strong>: Orphan disease designation supports <strong>premium pricing<\/strong> and <strong>accelerated regulatory pathways<\/strong><\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-competitive-differentiation\">Competitive Differentiation<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>First-Mover Advantage<\/strong>: World&#8217;s first 4-1BB bispecific in pivotal trials creates substantial competitive moat<\/li>\n\n\n\n<li><strong>Safety Profile<\/strong>: Bispecific design potentially avoids <strong>systemic 4-1BB activation<\/strong> toxicity seen with monospecific agonists<\/li>\n\n\n\n<li><strong>Broader Applicability<\/strong>: Mechanism suggests potential expansion beyond EP-NEC to other <strong>immune-cold tumors<\/strong><\/li>\n\n\n\n<li><strong>Platform Validation<\/strong>: Success validates X-body platform for additional bispecific candidates in pipeline<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-strategic-implications-for-leads-biolabs\">Strategic Implications for Leads Biolabs<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Global Leadership<\/strong>: Establishes Leads Biolabs as pioneer in <strong>4-1BB bispecific antibody development<\/strong><\/li>\n\n\n\n<li><strong>Pipeline De-risking<\/strong>: Pivotal trial success could support <strong>accelerated approval<\/strong> and rapid commercial launch<\/li>\n\n\n\n<li><strong>Partnership Value<\/strong>: Strong clinical data likely to attract <strong>global pharmaceutical partnership interest<\/strong><\/li>\n\n\n\n<li><strong>Valuation Catalyst<\/strong>: First-in-class status in high-value immuno-oncology space supports significant valuation upside<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-development-timeline-amp-regulatory-strategy\">Development Timeline &amp; Regulatory Strategy<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Phase III Initiation<\/strong>: Expected to begin <strong>Q3-Q4 2026<\/strong> with rapid enrollment due to single-arm design<\/li>\n\n\n\n<li><strong>Primary Endpoint<\/strong>: Likely objective response rate (ORR) or progression-free survival (PFS)<\/li>\n\n\n\n<li><strong>Accelerated Pathway<\/strong>: Single-arm pivotal design suggests pursuit of <strong>conditional\/accelerated approval<\/strong><\/li>\n\n\n\n<li><strong>Global Expansion<\/strong>: Success in China likely to support <strong>parallel FDA\/EMA filings<\/strong><\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-broader-therapeutic-potential\">Broader Therapeutic Potential<\/h2>\n\n\n\n<p>While initially focused on EP-NEC, opamtistomig&#8217;s mechanism suggests applicability across multiple tumor types:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Immune-Cold Tumors<\/strong>: Tumors resistant to current checkpoint inhibitors may respond to dual PD-L1\/4-1BB approach<\/li>\n\n\n\n<li><strong>Combination Opportunities<\/strong>: Potential synergy with <strong>chemotherapy, radiation, or other immunotherapies<\/strong><\/li>\n\n\n\n<li><strong>Biomarker Development<\/strong>: PD-L1 expression and 4-1BB presence may guide patient selection<\/li>\n\n\n\n<li><strong>Platform Extension<\/strong>: X-body technology enables rapid development of additional bispecific combinations<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-investment-considerations\">Investment Considerations<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Risk-Reward Profile<\/strong>: Pivotal trial represents major value inflection point with binary outcome<\/li>\n\n\n\n<li><strong>Market Timing<\/strong>: 4-1BB field heating up with multiple companies pursuing different approaches<\/li>\n\n\n\n<li><strong>Manufacturing Readiness<\/strong>: Complex bispecific production requires sophisticated capabilities already demonstrated<\/li>\n\n\n\n<li><strong>Intellectual Property<\/strong>: Patented X-body platform provides strong protection against competitors<\/li>\n<\/ul>\n\n\n\n<p><strong>Forward-Looking Statements<\/strong><br>This brief contains forward-looking statements regarding clinical development, regulatory approvals, and commercial expectations for opamtistomig. Actual results may differ due to risks including clinical trial outcomes, regulatory decisions, competitive dynamics, and market adoption patterns.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n\n\n\n<div data-wp-interactive=\"core\/file\" class=\"wp-block-file\"><object data-wp-bind--hidden=\"!state.hasPdfPreview\" hidden class=\"wp-block-file__embed\" data=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/05\/2026051900050_c.pdf\" type=\"application\/pdf\" style=\"width:100%;height:600px\" aria-label=\"Embed of 2026051900050_c.\"><\/object><a id=\"wp-block-file--media-6a37294e-fcf1-45b4-97e9-c37716d595e2\" href=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/05\/2026051900050_c.pdf\">2026051900050_c<\/a><a href=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/05\/2026051900050_c.pdf\" class=\"wp-block-file__button wp-element-button\" download aria-describedby=\"wp-block-file--media-6a37294e-fcf1-45b4-97e9-c37716d595e2\">Download<\/a><\/div>\n","protected":false},"excerpt":{"rendered":"<p>Nanjing Leads Biolabs Co., Ltd. (HKG: 9887) announced it has received regulatory clearance in China&#8230;<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,11],"tags":[16,62,4242,1974,28,18],"class_list":["post-65711","post","type-post","status-publish","format-standard","hentry","category-company","category-drug","tag-cancer","tag-clinical-trial-approval-initiation","tag-hkg-9887","tag-leads-biolabs","tag-multi-specific-antibodies","tag-pd-1-l1"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v27.5 (Yoast SEO v27.6) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Leads Biolabs&#039; Opamtistomig Becomes World&#039;s First 4-1BB Bispecific Antibody to Enter Pivotal Phase III for EP-NEC - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Nanjing Leads Biolabs Co., Ltd. (HKG: 9887) announced it has received regulatory clearance in China to initiate a Phase III clinical study evaluating opamtistomig (LBL-024) in combination with platinum chemotherapy for patients with advanced extrapulmonary neuroendocrine carcinoma (EP-NEC). The bispecific antibody represents the world&#039;s first molecule targeting the co-stimulatory receptor 4-1BB to advance to a single-arm pivotal clinical stage, leveraging Leads Biolabs&#039; proprietary X-body technology platform.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=65711\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Leads Biolabs&#039; Opamtistomig Becomes World&#039;s First 4-1BB Bispecific Antibody to Enter Pivotal Phase III for EP-NEC\" \/>\n<meta property=\"og:description\" content=\"Nanjing Leads Biolabs Co., Ltd. (HKG: 9887) announced it has received regulatory clearance in China to initiate a Phase III clinical study evaluating opamtistomig (LBL-024) in combination with platinum chemotherapy for patients with advanced extrapulmonary neuroendocrine carcinoma (EP-NEC). The bispecific antibody represents the world&#039;s first molecule targeting the co-stimulatory receptor 4-1BB to advance to a single-arm pivotal clinical stage, leveraging Leads Biolabs&#039; proprietary X-body technology platform.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=65711\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2026-05-19T15:16:43+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-05-19T15:16:44+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2560\" \/>\n\t<meta property=\"og:image:height\" content=\"1894\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=65711#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=65711\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Leads Biolabs&#8217; Opamtistomig Becomes World&#8217;s First 4-1BB Bispecific Antibody to Enter Pivotal Phase III for EP-NEC\",\"datePublished\":\"2026-05-19T15:16:43+00:00\",\"dateModified\":\"2026-05-19T15:16:44+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=65711\"},\"wordCount\":615,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"keywords\":[\"Cancer\",\"Clinical trial approval \\\/ initiation\",\"HKG: 9887\",\"Leads Biolabs\",\"Multi-specific antibodies\",\"PD-1\\\/L1\"],\"articleSection\":[\"Company\",\"Drug\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=65711#respond\"]}],\"copyrightYear\":\"2026\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=65711\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=65711\",\"name\":\"Leads Biolabs' Opamtistomig Becomes World's First 4-1BB Bispecific Antibody to Enter Pivotal Phase III for EP-NEC - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"datePublished\":\"2026-05-19T15:16:43+00:00\",\"dateModified\":\"2026-05-19T15:16:44+00:00\",\"description\":\"Nanjing Leads Biolabs Co., Ltd. (HKG: 9887) announced it has received regulatory clearance in China to initiate a Phase III clinical study evaluating opamtistomig (LBL-024) in combination with platinum chemotherapy for patients with advanced extrapulmonary neuroendocrine carcinoma (EP-NEC). The bispecific antibody represents the world's first molecule targeting the co-stimulatory receptor 4-1BB to advance to a single-arm pivotal clinical stage, leveraging Leads Biolabs' proprietary X-body technology platform.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=65711#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=65711\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=65711#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Leads Biolabs&#8217; Opamtistomig Becomes World&#8217;s First 4-1BB Bispecific Antibody to Enter Pivotal Phase III for EP-NEC\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Leads Biolabs' Opamtistomig Becomes World's First 4-1BB Bispecific Antibody to Enter Pivotal Phase III for EP-NEC - Insight, China&#039;s Pharmaceutical Industry","description":"Nanjing Leads Biolabs Co., Ltd. (HKG: 9887) announced it has received regulatory clearance in China to initiate a Phase III clinical study evaluating opamtistomig (LBL-024) in combination with platinum chemotherapy for patients with advanced extrapulmonary neuroendocrine carcinoma (EP-NEC). The bispecific antibody represents the world's first molecule targeting the co-stimulatory receptor 4-1BB to advance to a single-arm pivotal clinical stage, leveraging Leads Biolabs' proprietary X-body technology platform.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=65711","og_locale":"en_US","og_type":"article","og_title":"Leads Biolabs' Opamtistomig Becomes World's First 4-1BB Bispecific Antibody to Enter Pivotal Phase III for EP-NEC","og_description":"Nanjing Leads Biolabs Co., Ltd. (HKG: 9887) announced it has received regulatory clearance in China to initiate a Phase III clinical study evaluating opamtistomig (LBL-024) in combination with platinum chemotherapy for patients with advanced extrapulmonary neuroendocrine carcinoma (EP-NEC). The bispecific antibody represents the world's first molecule targeting the co-stimulatory receptor 4-1BB to advance to a single-arm pivotal clinical stage, leveraging Leads Biolabs' proprietary X-body technology platform.","og_url":"https:\/\/flcube.com\/?p=65711","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2026-05-19T15:16:43+00:00","article_modified_time":"2026-05-19T15:16:44+00:00","og_image":[{"width":2560,"height":1894,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","type":"image\/jpeg"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=65711#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=65711"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Leads Biolabs&#8217; Opamtistomig Becomes World&#8217;s First 4-1BB Bispecific Antibody to Enter Pivotal Phase III for EP-NEC","datePublished":"2026-05-19T15:16:43+00:00","dateModified":"2026-05-19T15:16:44+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=65711"},"wordCount":615,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"keywords":["Cancer","Clinical trial approval \/ initiation","HKG: 9887","Leads Biolabs","Multi-specific antibodies","PD-1\/L1"],"articleSection":["Company","Drug"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=65711#respond"]}],"copyrightYear":"2026","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=65711","url":"https:\/\/flcube.com\/?p=65711","name":"Leads Biolabs' Opamtistomig Becomes World's First 4-1BB Bispecific Antibody to Enter Pivotal Phase III for EP-NEC - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"datePublished":"2026-05-19T15:16:43+00:00","dateModified":"2026-05-19T15:16:44+00:00","description":"Nanjing Leads Biolabs Co., Ltd. (HKG: 9887) announced it has received regulatory clearance in China to initiate a Phase III clinical study evaluating opamtistomig (LBL-024) in combination with platinum chemotherapy for patients with advanced extrapulmonary neuroendocrine carcinoma (EP-NEC). The bispecific antibody represents the world's first molecule targeting the co-stimulatory receptor 4-1BB to advance to a single-arm pivotal clinical stage, leveraging Leads Biolabs' proprietary X-body technology platform.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=65711#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=65711"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=65711#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Leads Biolabs&#8217; Opamtistomig Becomes World&#8217;s First 4-1BB Bispecific Antibody to Enter Pivotal Phase III for EP-NEC"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/65711","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=65711"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/65711\/revisions"}],"predecessor-version":[{"id":65713,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/65711\/revisions\/65713"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=65711"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=65711"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=65711"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}